Fact Source: Financial Supervisory Service DART / 2025-10-10
Disclosure Type: Investment Caution Notice for Stock Futures & Options
💡 3-Second Summary
Following the decision for a corporate split, the final trading day for stock futures and options based on Samsung Biologics will be changed to October 29, 2025, and no new contract months will be listed after a specific period.
📊 1. [Key Disclosure Content & Summary of Financial Figures]
- Underlying Asset: Samsung Biologics Common Stock
- Reason for Market Action: Corporate split decision by Samsung Biologics Co., Ltd. (Pursuant to Article 27 of the Derivatives Market Business Regulations, etc.)
- Affected Contracts (Final Trading Day Adjustment): Stock Futures & Options for Nov ’25, Dec ’25, Jan ’26, Mar ’26, Jun ’26, and Sep ’26 contracts
- Revised Final Trading Day: October 29, 2025 (The trading day immediately preceding the start date of trading suspension for the underlying stock)
- Suspension of New Contract Listings: No new contract months will be listed after the General Meeting of Shareholders’ approval date (October 17, 2025) for the corporate split
- Other Material Information:
- Adjustments to base prices, trading multipliers, open interest, and strike prices, as well as the delisting of futures spread contracts, are all marked as not applicable (-).
- Details regarding the new listing of Samsung Biologics stock futures and options will be announced in the future.
- The above plan may be subject to change depending on the schedule and outcome of the company’s General Meeting of Shareholders.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This announcement serves to guide technical adjustments and schedules within the derivatives market resulting from the previously decided corporate split, rather than reflecting changes in the company’s financial figures or business fundamentals. Consequently, investors trading the relevant stock futures and options should clearly verify the changed final trading day of October 29 and take the schedule into account.
The modification of the final trading day and the suspension of new contract listings could lead to changes in trading conditions within the derivatives market, which may vary depending on the outcome of the upcoming General Meeting of Shareholders. Investors may need to closely monitor related disclosures and upcoming announcements to track specific schedules concerning the trading suspension of the underlying cash stock.
📝 Editor’s Comment (by K-STOCK Editor)
Market measures for stock futures and options have been disclosed in accordance with Samsung Biologics’ corporate split process. The core takeaways from this announcement are that the final trading day for certain stock futures and options will be changed to October 29, and no new contract months will be listed after the shareholder meeting approval date. Investors engaged in related derivatives trading must check these schedule changes, and it remains prudent to verify the detailed cash market process, such as the exact trading suspension start date, through upcoming official disclosures.
📢 Disclaimer & Source Information
Source: This content has been structured and newly generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
